MedTrace Logo

Alpha Lipoic Acid Effect on No-Reflow Phenomenon

NCT05360602 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2024-11-05

No results posted yet for this study

Summary

Prospective, randomized, open-label, controlled clinical trial to evaluate the efficacy and tolerability of Alpha Lipoic Acid administration on oxidative stress, inflammatory markers, clinical outcome and occurrence of No-Reflow in post myocardial infarction (MI) patients by assessment of aldehyde dehydrogenase-2 (ALDH2) as a marker of oxidative stress and paraoxonase-1 (PON-1) as a marker of oxidative stress and inflammation.

Conditions

  • No-Reflow Phenomenon

Interventions

DRUG

The standard care for post-PCI MI

will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.

DIETARY_SUPPLEMENT

Alpha Lipoic Acid plus the standard care for post-PCI MI

Intravenous and oral administration of Alpha Lipoic Acid 600 mg plus the standard care for post-PCI MI which will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Ayman M Saleh, MD · Faculty of Medicine, Ain Shams University

  • Lamiaa M El Wakeel, PhD · Faculty of Pharmacy, Ain Shams University

  • Marwa Adel Ahmed, PhD · Faculty of Pharmacy, Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2023-07-01
Completion
2024-01-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05360602 on ClinicalTrials.gov